Fate Therapeutics FATE 深 滬
等待開盤 08-01 09:30:00 美东时间
2.45
-0.060
-2.39%
華盛通- 最 高2.555
- 今 開2.51
- 成交量 145.92万股
- 最 低 2.39
- 昨 收 2.51
- 總市值 2.86亿
- 52周最高 3.23
- 市盈率 靜 --
- 換手率 1.25%
- 52周最低 0.91
- 委 比 -95.03%
- 總股本 1.17亿
- 歷史最高 121.16
- 量 比 1.17
- 振 幅 6.57%
- 歷史最低 0.6611
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures gaining around 100 points on Wednesday. Shares of Phoenix Education Partners Inc (NYSE:PXED) fell sharply in pre-market trading after the company reported third-quarter financial results and cut its FY26 sales guidance b...
07-15 20:02
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical...
07-06 20:43
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Fate Therapeutics shares are trading lower. The company presented clinical data this weekend featuring its off-the-shelf CAR T-cell program FT836 at ASCO Annual Meeting.
Fate Therapeutics shares are trading lower. The company presented clinical data...
06-01 23:05
Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annual Meetings
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
05-21 20:34
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from
05-13 20:33
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to
05-11 20:33
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
05-07 01:35
美股牛股 | AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，光互连概念POET单日反弹逾29%
AI“带飞”建筑巨头！STRL绩后股价狂飙逾50%，Q1营收猛增91%；光互连概念POET单日反弹逾29%>>
05-06 19:14
美股牛股 | 多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%
多重利好！Circle大涨近20%，CLARITY法案取得关键进展并获但斌买入；GBTG飙升超57%，获Long Lake以63亿美元收购>>
05-05 18:24
